Section Arrow
Quote
CRSP.NASDAQ
- CRISPR Therapeutics AG
Quotes are at least 15-min delayed:2024/05/16 04:36 EDT
Last
 56.96
+1.25 (+2.24%)
Day High 
58.75 
Prev. Close
55.71 
1-M High
60.95 
Volume 
1.49M 
Bid
56.7
Ask
59.7
Day Low
56.39 
Open
57.93 
1-M Low
51.02 
Market Cap 
4.73B 
Currency USD 
P/E -- 
%Yield 0 
10-SMA 54.67 
20-SMA 54.83 
50-SMA 63.77 
52-W High 91.1 
52-W Low 37.55 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.70/-2.09
Enterprise Value
4.95B
Balance Sheet
Book Value Per Share
24.54
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
370.00M
Operating Revenue Per Share
2.00
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.8391-0.0237-2.75%-- 
NVAXNovavax12.9-0.58-4.30%-- 
JAGXJaguar Health0.2551-0.0198-7.20%-- 
OCGNOcugen1.96+0.26+15.29%-- 
ARQTArcutis Biotherapeutics9.24+1.11+13.65%-- 
Quotes are at least 15-min delayed：2024/05/16 04:36 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), whichis a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.